A Melbourne start-up owned by a small group of medical researchers has landed one of Australia’s biggest potential biotech licensing deals after Japanese pharmaceutical giant Astellas Pharma agreed to pay up to $2 billion for future rights to develop and commercialise its new cancer treatment.
Audax Biosciences, an immunotherapy start-up founded and largely self-funded by scientists Jai Rautela and Nicholas Huntington, said the deal was a sign of confidence in its treatment, which has not yet been tested in humans.
Gift articles to anyone you choose each month when you subscribe.
